Aptose Biosciences, Inc. News Releases http://ir.aptose.com/ Aptose Biosciences, Inc. News Releases en Aptose Biosciences Establishes New At-The-Market Facility http://ir.aptose.com/news-releases/news-release-details/aptose-biosciences-establishes-new-market-facility-1 SAN DIEGO and TORONTO , May 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that it has entered into an Fri, 24 May 2019 17:43:00 -0400 Aptose Biosciences, Inc. News Releases 12726 Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association http://ir.aptose.com/news-releases/news-release-details/aptose-present-new-preclinical-data-cg-806-24th-congress SAN DIEGO and TORONTO , May 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for Thu, 16 May 2019 10:02:00 -0400 Aptose Biosciences, Inc. News Releases 12691 Aptose to Present at May Investor Conferences http://ir.aptose.com/news-releases/news-release-details/aptose-present-may-investor-conferences SAN DIEGO and TORONTO , May 13, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of Mon, 13 May 2019 08:15:00 -0400 Aptose Biosciences, Inc. News Releases 12676 Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC http://ir.aptose.com/news-releases/news-release-details/aptose-announces-commencement-previously-announced-200-million Obtains NASDAQ, Toronto Stock Exchange Approval SAN DIEGO and TORONTO , May 10, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of Fri, 10 May 2019 19:24:00 -0400 Aptose Biosciences, Inc. News Releases 12656 Aptose Reports Results for the First Quarter Ended March 31, 2019 http://ir.aptose.com/news-releases/news-release-details/aptose-reports-results-first-quarter-ended-march-31-2019 ─  Patient Dosed at Second Dose Level in APTO-253 Clinical Trial ─ ─  Patient Screening Initiated for CG-806 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today SAN DIEGO and TORONTO , May 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: Tue, 07 May 2019 16:01:00 -0400 Aptose Biosciences, Inc. News Releases 12621 Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019 http://ir.aptose.com/news-releases/news-release-details/aptose-present-bloom-burton-co-healthcare-investor-conference-1 SAN DIEGO and TORONTO , April 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of Wed, 24 Apr 2019 07:30:00 -0400 Aptose Biosciences, Inc. News Releases 12586 Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019 http://ir.aptose.com/news-releases/news-release-details/aptose-release-first-quarter-ended-march-31-2019-financial SAN DIEGO and TORONTO , April 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of Tue, 23 Apr 2019 07:30:00 -0400 Aptose Biosciences, Inc. News Releases 12581 Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference http://ir.aptose.com/news-releases/news-release-details/aptose-present-hc-wainwright-annual-global-life-sciences-1 SAN DIEGO and TORONTO, April 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Tue, 02 Apr 2019 07:00:00 -0400 Aptose Biosciences, Inc. News Releases 12541 Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting http://ir.aptose.com/news-releases/news-release-details/aptose-presents-new-preclinical-data-cg-806-and-apto-253-2019 Pan-FLT3/pan-BTK inhibitor CG-806 Demonstrates Significant and Superior Potency Against Primary Cells Across AML Types –   MYC Inhibitor APTO-253 Potently Kills Hematologic Cell Lines; Mechanism of Action Further Defined – SAN DIEGO and TORONTO , April 01, 2019 (GLOBE NEWSWIRE) -- Aptose Mon, 01 Apr 2019 13:00:00 -0400 Aptose Biosciences, Inc. News Releases 12526 Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806 http://ir.aptose.com/news-releases/news-release-details/aptose-announces-fda-allowance-investigational-new-drug – CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory CLL and B cell malignancies planned to initiate in Q2/2019 – SAN DIEGO and TORONTO , March 25, 2019 Mon, 25 Mar 2019 07:02:00 -0400 Aptose Biosciences, Inc. News Releases 12496